title: Alzheimer's disease vaccine development: A new strategy focusing on immune modulation.
abstract: Despite significant advances in the development of Alzheimer's disease (AD) vaccines effective in animal models, these prototypes have been clinically unsuccessful; apparently the result of using immunogens modified to prevent inflammation. Hence, a new paradigm is needed that uses entire AD-associated immunogens, a notion supported by recent successful passive immunotherapy results, with adjuvants that induce Th2-only while inhibiting without abrogating Th1 immunity. Here, we discuss the obstacles to AD vaccine development and Th2-adjuvants that by acting on dendritic and T cells, would elicit regardless of the antigen a safe and effective antibody response, while preventing damaging neuroinflammation and ameliorating immunosenescence.
authors.affiliation: Qantu Therapeutics, Inc., 612 E. Main Street, Lewisville, TX 75057, USA. Electronic address: dmarciani@earthlink.net.
authors.forename: Dante J
authors.initials: DJ
authors.lastname: Marciani
mesh_terms: D000544:Alzheimer Disease / Q000276:immunology* / Q000628:therapy*; D023582:Alzheimer Vaccines / Q000276:immunology*; D000818:Animals; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*
chemical_list: D023582:Alzheimer Vaccines
keywords: Adjuvants; Aldehydes; Alzheimer's vaccine; Beta-amyloid; Fucosylated glycosides; Immunomodulation; Tau protein